Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

April F Eichler

Showing results (11-20 of 27) with videos related to

Pageof 3
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 2, 2009
Use of video to facilitate end-of-life discussions with patients with cancer: a randomized controlled trialAreej El-Jawahri, Lisa M Podgurski, April F Eichler, et al.
Journal of Neuro-Oncology|September 8, 2010
Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard radiation and temozolomideElizabeth R Gerstner, April F Eichler, Scott R Plotkin, et al.
Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia|June 10, 2016
Impact of histopathological transformation and overall survival in patients with progressive anaplastic gliomaAllen L Ho, Matthew J Koch, Shota Tanaka, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 8, 2009
Polysomy for chromosomes 1 and 19 predicts earlier recurrence in anaplastic oligodendrogliomas with concurrent 1p/19q lossMatija Snuderl, April F Eichler, Keith L Ligon, et al.
The Oncologist|June 11, 2020
Pemetrexed in Recurrent or Progressive Central Nervous System Lymphoma: A Phase I Multicenter Clinical TrialJorg Dietrich, Laura Versmee, Jan Drappatz, et al.
Journal of Neuro-Oncology|December 16, 2014
Vandetanib plus sirolimus in adults with recurrent glioblastoma: results of a phase I and dose expansion cohort studyMilan G Chheda, Patrick Y Wen, Fred H Hochberg, et al.
NPJ Precision Oncology|December 5, 2017
Early changes in glioblastoma metabolism measured by MR spectroscopic imaging during combination of anti-angiogenic cediranib and chemoradiation therapy are associated with survivalOvidiu C Andronesi, Morteza Esmaeili, Ronald J H Borra, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 17, 2012
Combined targeting of HER2 and VEGFR2 for effective treatment of HER2-amplified breast cancer brain metastasesDavid P Kodack, Euiheon Chung, Hiroshi Yamashita, et al.
Neuro-Oncology|July 6, 2013
Increase in tumor-associated macrophages after antiangiogenic therapy is associated with poor survival among patients with recurrent glioblastomaChristine Lu-Emerson, Matija Snuderl, Nathaniel D Kirkpatrick, et al.
Breast Cancer Research and Treatment|November 8, 2013
A phase I study of lapatinib with whole brain radiotherapy in patients with Human Epidermal Growth Factor Receptor 2 (HER2)-positive breast cancer brain metastasesNancy U Lin, Rachel A Freedman, Naren Ramakrishna, et al.
Pageof 3

Showing results (11-20 of 27) with videos related to

Sort By:
Pageof 3
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 2, 2009
Use of video to facilitate end-of-life discussions with patients with cancer: a randomized controlled trialAreej El-Jawahri, Lisa M Podgurski, April F Eichler, et al.
Journal of Neuro-Oncology|September 8, 2010
Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard radiation and temozolomideElizabeth R Gerstner, April F Eichler, Scott R Plotkin, et al.
Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia|June 10, 2016
Impact of histopathological transformation and overall survival in patients with progressive anaplastic gliomaAllen L Ho, Matthew J Koch, Shota Tanaka, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 8, 2009
Polysomy for chromosomes 1 and 19 predicts earlier recurrence in anaplastic oligodendrogliomas with concurrent 1p/19q lossMatija Snuderl, April F Eichler, Keith L Ligon, et al.
The Oncologist|June 11, 2020
Pemetrexed in Recurrent or Progressive Central Nervous System Lymphoma: A Phase I Multicenter Clinical TrialJorg Dietrich, Laura Versmee, Jan Drappatz, et al.
Journal of Neuro-Oncology|December 16, 2014
Vandetanib plus sirolimus in adults with recurrent glioblastoma: results of a phase I and dose expansion cohort studyMilan G Chheda, Patrick Y Wen, Fred H Hochberg, et al.
NPJ Precision Oncology|December 5, 2017
Early changes in glioblastoma metabolism measured by MR spectroscopic imaging during combination of anti-angiogenic cediranib and chemoradiation therapy are associated with survivalOvidiu C Andronesi, Morteza Esmaeili, Ronald J H Borra, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 17, 2012
Combined targeting of HER2 and VEGFR2 for effective treatment of HER2-amplified breast cancer brain metastasesDavid P Kodack, Euiheon Chung, Hiroshi Yamashita, et al.
Neuro-Oncology|July 6, 2013
Increase in tumor-associated macrophages after antiangiogenic therapy is associated with poor survival among patients with recurrent glioblastomaChristine Lu-Emerson, Matija Snuderl, Nathaniel D Kirkpatrick, et al.
Breast Cancer Research and Treatment|November 8, 2013
A phase I study of lapatinib with whole brain radiotherapy in patients with Human Epidermal Growth Factor Receptor 2 (HER2)-positive breast cancer brain metastasesNancy U Lin, Rachel A Freedman, Naren Ramakrishna, et al.
Pageof 3